The following study involved 367,439 non-diabetic patients, including those on GLP-1 and other weight-loss medications.
During the analysis, factors such as patient sex, social vulnerability, BMI classification, race, ethnicity, and age were considered.
For patients prescribed liraglutide, there was an increased likelihood of delayed gastric emptying (139%) and ileus (32%) compared to those on non-GLP-1 weight loss medications. However, there was no significant difference in the likelihood of gallstones.
For patients prescribed semaglutide, there was a 39% increase in the possibility of delayed gastric emptying and gallstones but no significant change in the likelihood of ileus.
As a result, for most patients with gastroparesis, ileus, or symptomatic gallstones, GLP-1 agonists are contraindicated since they can exacerbate their conditions.